Synthetic biology

#DNA #Drug discovery #Synthetic biology

Unlocking the potential of synthetic DNA 

Raquel Sanches-Kuiper, Vice President of Science and Applications at Evonetix, and Clare Whitewoods, Marketing Communications Manager at Evonetix, look at the benefits synthetic DNA brings to pharmaceutical development.  Engineering biology is reshaping the world, from enabling the rapid development of vaccines to providing alternatives to petroleum fuels. The rapid progress… Read More

#Exclusive Content

#Assay #Biologics / Biotechnology #Biopharma #Diversity #DNA #Drug development #Drug discovery #Gene sequencing #Ingredients / APIs / Fine chemicals #Synthetic biology #Women in Discovery #Women in STEM

New podcast: Overcoming different barriers in drug discovery

This is the latest episode of the free DDW narrated podcast, “Overcoming different barriers in drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Addressing the challenge of salt forms in drug discovery”, “… Read More

#News

Synthetic DNA molecule
#Drug discovery #In Focus Report #Synthetic biology #Synthetic DNA

In depth eReport on Synthetic Biology: Is it the next big thing?

Synthetic biology has shown significant potential to the drug discovery sector. Although not a new area of science, the prominence of this technology and its applications – evident during the Covid-19 pandemic – have increased of late. This has created advances in the development of new medicines and our… Read More

#Editor's Choice #News

#Drug discovery #In Focus Report #Synthetic biology #Synthetic DNA

Synthetic Biology: Is it the next big thing?

Download this exclusive DDW eReport to learn more about: The global market for synthetic biology: its potential and where innovative drug development is taking place Analysis of regional markets and the key players within the synthetic biology sector How advances in the synthetic biology field are impacting drug discovery – from… Read More

#DDW eBooks #DDW In Focus eReports #Intelligence

#bit bio #Cell programming #iPSC #Synthetic biology #US patent

bit.bio secures foundational US patent for opti-ox

bit.bio has secured a foundational US patent for opti-ox, its precision cell programming and manufacturing technology. opti-ox uses a dual genomic safe harbour approach to cell programming, and the granted US patent covers the use of opti-ox to deterministically activate genetic code in any eukaryotic (cell with a nucleus) cell… Read More

#Business & Investment #News

Genetic research
#CAR-T #Drug development #Drug discovery #Synthetic biology

Synthetic biology: Innovating in drug discovery

Listen to this article on the DDW Podcast: Synthetic biology is increasingly important to drug discovery and development. Reece Armstrong examines recent activity within the sector and highlights some of the key advancements and innovation. Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company… Read More

#Exclusive Content

Synthetic DNA
#Biotherapeutics #DNA #Synthetic biology #Synthetic DNA

Accelerating biotherapy and personalised medicine with long DNA

Listen to this article on the DDW Podcast: Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. With advanced technology and a growing understanding of the underlying biology, biotherapy development has evolved. Since 2010, investments in the… Read More

#Exclusive Content

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

DDW Highlights podcast: New episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

This week in drug discovery (3-7 July)  

News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. Despite the bad news for the UK life sciences industry this week that international investment dropped nearly 50% in 2022, both private and public funding activity has continued apace in the wider drug discovery… Read More

#News

#Camena Bioscience #Financing #Funding #Genetics / genomics #Synthetic biology

Synthetic biology company raises $10m in financing round

Camena Bioscience has closed a $10m Series A financing round, which will be used to scale operations and continue development of DNA synthesis platform gSynth. Synthetic genes are widely used by researchers to understand the mechanisms of disease, and in the drug discovery process to combat… Read More

#News

Gene editing
#bit bio #CRISPR #Drug discovery #Stem cells #Synthetic biology #Synthetic DNA

Synthetic biology: Impacting drug discovery

Listen to this article on the DDW Podcast: Mark Kotter, Founder and CEO of bit.bio, talks with Reece Armstrong about different approaches to synthetic biology and its applications in programming stem cells into mature, functional human cells for drug discovery and the creation of next generation. In the last 10 years,… Read More

#Exclusive Content

DNA
#Biology #Evonetix #Synthetic biology #Synthetic DNA #University of Cambridge

Desktop DNA synthesis could ‘revolutionise’ engineering biology

The first DNA synthesised using Evonetix’s semiconductor chip technology has been delivered to the Department of Chemical Engineering and Biotechnology at the University of Cambridge. The DNA was delivered to Dr Jenny Molloy, Co-chair of the Engineering Biology Interdisciplinary Research Centre at the University of Cambridge. Read More

#News

Woman with alcohol use disorder
#Beckley Psytech #Phase II trial #Psychedelics #Substance use disorders #Synthetic biology

Phase IIa study will investigate psychedelic for alcohol use disorder

Beckley Psytech has initiated a Phase IIa study investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD). BPL-003 is Beckley Psytech’s novel synthetic formulation of the psychedelic compound 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery… Read More

#News

#AI / data analytics / healthtech / informatics #Automation / robotics #Ginkgo Bioworks #Lab automation #Lab technology #SLAS2023 #Synthetic biology

Connecting lab automation to decision-making

Ashwin Pillai is Test Engineer 3 in HTS & Assay Development at Ginkgo Bioworks, a company whose mission is to make biology easier to engineer. Ahead of his presentation in the Automation Technologies Track at SLAS2023, Pillai shares insight on data and how we can connect lab automation to decisions. Read More

#Exclusive Content

#DNA #Financing #Funding #Investment #Synthetic biology

$24 million funding to accelerate synthetic biology research

Evonetix has completed a $24 million financing round, extending its total series B funding to over $54 million.   The fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round.  The investment will enable the continued development… Read More

#Business & Investment #News

#AI #Biopharma #Biopharmaceuticals #Comment #DNA #Lab automation #SLAS2022 #Synthetic biology

Podcast: The impact of synthetic biology and collaboration in pharma

This is the latest episode of the free DDW podcast. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Why synthetic biology is the next big thing for biopharma” and “Collaborative spirit helps drive innovation”. ‘Can synthetic biology save… Read More

#News